勃起功能障碍（ED）市场规模、份额和成长分析（按治疗方法、最终用户和地区划分）—2026-2033年产业预测

全球勃起功能障碍（ED）市场规模预计在 2024 年达到 27.2 亿美元，从 2025 年的 29.6 亿美元增长到 2033 年的 58.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.8%。

勃起功能障碍，即在性生活中无法达到或维持令人满意的阴茎勃起，是男性性健康的常见问题，严重影响其身心健康。其病因主要分为两类：心理因素和生理因素，后者包括高血压、高胆固醇、肥胖、糖尿病和吸烟等生活型态因素。由于该疾病盛行率不断上升，勃起功能障碍治疗市场持续成长。预计市场参与企业将对现有治疗方法有更深入的了解。然而，阴茎植入的高昂费用是市场扩张面临的一大挑战，这可能会阻碍许多男性寻求有效的解决方案。

全球勃起功能障碍市场驱动因素

全球勃起功能障碍市场的主要驱动力是糖尿病、肥胖症和心血管疾病的日益普遍，而这些疾病又与不健康的生活方式密切相关。随着老龄化，这些健康问题愈发突出，并导致勃起功能障碍的发生。尤其在许多开发中国家，年轻人的压力水平不断上升，蒸馏、即食食品、酒精和烟草的消费量也在增加。这些生活习惯会对整体健康产生负面影响，并增加勃起功能障碍的风险。此外，人口老化加剧了这个问题，进一步推动了全球对勃起功能障碍治疗的需求。

限制全球勃起功能障碍药物市场的因素

全球勃起功能障碍治疗市场面临许多挑战，包括销售量有限，尤其是中低收入国家。这主要是由于人们对现有治疗方法的认知度低，以及经济拮据导致购买力不足。此外，社会上不愿将此类治疗方法融入日常生活也加剧了这个问题。市场成长缓慢也与勃起功能障碍药物的副作用有关，例如头痛、消化器官系统问题、脸部潮红、鼻塞、视力障碍、头晕、腹泻和皮疹。这些副作用可能会阻碍潜在使用者寻求必要的治疗。

全球勃起功能障碍治疗市场趋势

全球勃起功能障碍药物市场正经历显着的成长，这主要得益于Sildenafil（通用名：威而钢）的有效性和广泛应用。该药物已成为治疗勃起功能障碍的第一线药物，许多使用者报告指出勃起功能已改善。随着人们对性健康问题的认识不断提高，以及围绕勃起功能障碍的社会污名逐渐消退，越来越多的男性开始寻求治疗方案。此外，对潜在新治疗方法的持续研究和治疗方法的进步也推动了市场成长。勃起功能障碍盛行率的不断上升进一步刺激了市场需求，使其成为全球医疗保健领域一个充满活力且不断发展的领域。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球勃起功能障碍（ED）市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 药物
• Sildenafil
• 他达拉非
• 伐地那非
• 阿伐那菲尔
• 其他的
• 阴茎植入
• 阴茎帮浦
• 其他的

全球勃起功能障碍（ED）市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 门诊手术中心
• 药局
• 其他的

全球勃起功能障碍（ED）市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer（US）
• Eli Lilly and Company（US）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Mylan（US）（Now Viatris）
• Viatris（US）
• Teva Pharmaceutical Industries（Israel）
• Sun Pharmaceutical Industries（India）
• Cipla（India）
• Aurobindo Pharma（India）
• Lupin Limited（India）
• Dr. Reddy's Laboratories（India）
• Sandoz（Switzerland）
• Novartis（Switzerland）
• Abbott Laboratories（US）
• Sanofi（France）
• GlaxoSmithKline（GSK）（UK）
• Johnson & Johnson（US）
• Boston Scientific（US）
• Coloplast（Denmark）

结论与建议

Global Erectile Dysfunction Market size was valued at USD 2.72 Billion in 2024 and is poised to grow from USD 2.96 Billion in 2025 to USD 5.81 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

Erectile dysfunction, characterized by the inability to achieve or maintain an adequate penile erection during sexual activity, is a prevalent issue in male sexual health that significantly impacts both physical and mental well-being. It arises from two primary factors: psychological and physiological, with the latter including conditions such as high blood pressure, high cholesterol, obesity, diabetes, and lifestyle choices like smoking. The market for erectile dysfunction treatments is witnessing growth driven by an increase in affected individuals. Market participants are expected to enhance their understanding of available treatments. However, a notable challenge to market expansion is the high cost associated with penile implants, which may hinder accessibility for many seeking effective solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Market Segments Analysis

Global Erectile Dysfunction Market is segmented by Treatment Type, End User and region. Based on Treatment Type, the market is segmented into Drugs, Sildenafil, Tadalafil, Vardenafil, Avanafil, Others, Penile Implants, Penis Pumps and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgery Centers, Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Erectile Dysfunction Market

The global erectile dysfunction market is significantly driven by the increasing prevalence of diabetes, obesity, and cardiovascular diseases, which are closely linked to unhealthy lifestyle choices. As individuals age, these health challenges become more pronounced, contributing to the incidence of erectile dysfunction. Particularly in many developing countries, younger populations experience heightened stress levels, leading to a surge in the consumption of fast food, ready-to-eat meals, alcohol, and tobacco. These lifestyle habits negatively impact overall health, thereby elevating the risk of erectile dysfunction. Furthermore, the rising senior population further exacerbates this issue, fueling demand for erectile dysfunction treatments worldwide.

Restraints in the Global Erectile Dysfunction Market

The global erectile dysfunction market faces significant challenges, particularly in low- and middle-income countries where sales are limited. This is largely due to a lack of awareness about available treatments, combined with economic constraints that hinder purchasing capabilities. Furthermore, societal reluctance to integrate such options into daily life exacerbates the situation. Additionally, the slow market growth can be linked to the adverse effects associated with erectile dysfunction medications, including headaches, digestive issues, facial flushing, nasal congestion, visual disturbances, dizziness, diarrhea, and skin rashes; these side effects can deter potential users from seeking necessary treatment.

Market Trends of the Global Erectile Dysfunction Market

The Global Erectile Dysfunction market is experiencing a significant upward trajectory, primarily driven by the efficacy and popularity of sildenafil, commonly known as Viagra. This medication has established itself as the first-line treatment for erectile dysfunction, with a substantial portion of users reporting improved erection quality. As awareness of sexual health issues increases and societal stigmas around discussing erectile dysfunction diminish, more men are seeking treatment options. Additionally, ongoing research into potential new therapies and advancements in treatment methods contribute to the market's growth. The rising prevalence of erectile dysfunction further fuels demand, making this an evolving and dynamic sector within the global healthcare landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Erectile Dysfunction Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Drugs
• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others
• Penile Implants
• Penis Pumps
• Others

Global Erectile Dysfunction Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgery Centers
• Pharmacies
• Others

Global Erectile Dysfunction Market Size & CAGR (2026-2033)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (US) (Now Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations